Protara Therapeutics, Inc.
TARA
$3.97
-$0.07-1.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -49.25% | -35.54% | -18.17% | -57.26% | -7.38% |
| Total Depreciation and Amortization | 8.43% | 13.41% | 4.76% | 18.07% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 56.45% | 12.56% | 8.20% | -38.49% | -33.76% |
| Change in Net Operating Assets | -33.95% | -129.30% | -111.15% | 314.68% | -394.42% |
| Cash from Operations | -45.06% | -82.10% | -47.64% | -59.36% | -41.76% |
| Capital Expenditure | -- | -- | 50.00% | 60.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 74.75% | -219.48% | 77.87% | -1,690.03% | -352.42% |
| Cash from Investing | 74.77% | -219.59% | 77.86% | -1,720.48% | -352.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -29.20% | -21.87% | -- | -99.51% | -- |
| Repurchase of Common Stock | -47.03% | -- | -- | 100.00% | -143.42% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 36.47% | 96.46% | -- | 92.95% | -- |
| Cash from Financing | -33.87% | -17.26% | -- | -99.98% | 2,376.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 51.05% | -66.58% | 49.91% | -260.55% | -664.15% |